To understand the mechanism of SARS-CoV-2 cell entry, it is essential to study how Spike proteins interact with the ACE2 receptor. However, such studies are hampered by the danger of producing and manipulating live coronavirus. Live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Pseudoviruses are useful virological tools because of their safety and versatility, the pseudovirus is restricted to a single round of replication and can be handled using BSL-2 containment practices.
Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike display antigenically correct spike protein pseudotyped (Wuhan-Hu-1 strain or D614G mutant) on replication-incompetent virus particles that contain a heterologous lentiviral (HIV) core and are capable of a single round of infection and carry a genome that expresses either a GFP or luciferase optical reporter gene upon infection.
Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike are produced in HEK-293T cells using three separate plasmids, encoding the spike protein, a lentiviral gag polyprotein, and a reporter gene and can be used to test the ability of serum, antibodies, and drugs to neutralize the infectivity of SARS-CoV- 2 spike protein.
Pseudotyped Luciferase/GFP VSV is designed as a control for CD’s Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike to test for non-specific factors that affect virus infectivity. The Pseudovirus display the VSV envelope glycoprotein (VSV-G) pseudotyped on replication-incompetent virus particles that contain a heterologous lentiviral (HIV) core. The VSV-G protein confers the Pseudovirus with a high level of single cycle infectivity due to its broad tropism.
The Pseudotyped Luciferase/GFP Lentivirus was produced without envelope glycoproteins such as VSV-G or SARS-CoV-2 spike. It contains the Luciferase gene or GFP driven by a CMV promoter as the reporter. Since the virus is lacking the envelope glycoproteins and cannot be transfected to target cells. The Pseudotyped Luciferase Lentivirus can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors.
|Cat.No.||Product Name||Reporter Gene||Envelope Glycoproteins|
|COV-PS01||Pseudotyped Luciferase rSARS-CoV-2 Spike||Luciferase||SARS-CoV-2 Spike (Wuhan-Hu-1)|
|COV-PS02||Pseudotyped GFP rSARS-CoV-2 Spike||GFP||SARS-CoV-2 Spike (Wuhan-Hu-1)|
|COV-PS03||Pseudotyped rSARS-CoV-2 Spike||×||SARS-CoV-2 Spike (Wuhan-Hu-1)|
|COVL-D641G||Pseudotyped Luciferase rSARS-CoV-2 Spike D614G||Luciferase||SARS-CoV-2 Spike (D614G)|
|COVG-D641G||Pseudotyped GFP rSARS-CoV-2 Spike D614G||GFP||SARS-CoV-2 Spike (D614G)|
|VSV-PS01||Pseudotyped Luciferase VSV||Luciferase||VSV-G|
|VSV-PS02||Pseudotyped GFP VSV||GFP||VSV-G|
|COV-PSL1||Pseudotyped Luciferase Lentivirus||Luciferase||×|
|COV-PSG2||Pseudotyped GFP Lentivirus||GFP||×|
|COV-PSV10||Pseudotyped VSV-SARS-CoV-2 S-ΔG-mCherry||mCherry||SARS-CoV-2 Spike (Wuhan-Hu-1)|
Our team has been working diligently to stay abreast these new developments and are currently developing a serial of Lentiviral SARS-CoV-2 Mutation Pseudovirus.
|Cat#||Product Name||Reporter Gene||Envelope Glycoproteins|
|COVL-B117||Pseudotyped Luciferase rSARS-CoV-2 Spike (Variant B.1.1.7)||Luciferase||SARS-CoV-2 Spike (Variant B.1.1.7; deletion 69-70, deletion 144, N501Y, A570D, D614G, P681H)|
|COVG-B117||Pseudotyped GFP rSARS-CoV-2 Spike (Variant B.1.1.7)||GFP||SARS-CoV-2 Spike (Variant B.1.1.7; deletion 69-70, deletion 144, N501Y, A570D, D614G, P681H)|
|COVL-N439K||Pseudotyped Luciferase rSARS-CoV-2 Spike (N439K)||Luciferase||SARS-CoV-2 Spike (N439K, D614G)|
|COVG-N439K||Pseudotyped GFP rSARS-CoV-2 Spike (N439K)||GFP||SARS-CoV-2 Spike (N439K, D614G)|
|COVL-501YV2||Pseudotyped Luciferase rSARS-CoV-2 Spike (Variant 501Y.V2)||Luciferase||SARS-CoV-2 Spike (Variant 501Y.V2; K417N, E484K, N501Y, D614G)|
|COVG-501YV2||Pseudotyped GFP rSARS-CoV-2 Spike (Variant 501Y.V2)||GFP||SARS-CoV-2 Spike (Variant 501Y.V2; K417N, E484K, N501Y, D614G)|